Evidence map›Paper›PMID 40982170›Full record

SynthesisJournal of gastrointestinal cancer2025

Efficacy and Safety of Dual Therapy with HER2-inhibitors (Pertuzumab and Trastuzumab) in Gastric or Gastroesophageal Tumors: A Systematic Review and Meta-analysis.

Geraldo Lucas Lopes Costa, João Victor Ramos da Cruz, José Roberto Alves, Saint Clair Vieira de Oliveira, Leticia Vieira Dos Santos Ribeiro, Arthur Henrique Gohr, Daniella Serafin Couto Vieira

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. HER2 expression andMediastinum (Hong Kong, China) · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Geraldo Lucas Lopes CostaMedical School of the Federal University of Santa Catarina, Trindade, Florianópolis, Santa Catarina, 88040-900, Brazil. gerrard_lucas@hotmail.com.ORCID http://orcid.org/0009-0002-0794-4605
João Victor Ramos da CruzMedical School of the Federal University of Santa Catarina, Trindade, Florianópolis, Santa Catarina, 88040-900, Brazil.ORCID http://orcid.org/0009-0009-3110-931X
José Roberto AlvesDepartment of Surgery of the Federal University of Santa Catarina, Florianópolis, SC, Brazil.ORCID http://orcid.org/0000-0002-0520-5190
Saint Clair Vieira de OliveiraDepartment of Surgery of the Federal University of Santa Catarina, Florianópolis, SC, Brazil.ORCID http://orcid.org/0000-0002-7565-0724
Leticia Vieira Dos Santos RibeiroMedical School of the Federal University of Santa Catarina, Trindade, Florianópolis, Santa Catarina, 88040-900, Brazil.ORCID http://orcid.org/0009-0001-5934-8488
Arthur Henrique GohrMedical School of the Federal University of Santa Catarina, Trindade, Florianópolis, Santa Catarina, 88040-900, Brazil.ORCID http://orcid.org/0009-0009-7305-4054
Daniella Serafin Couto VieiraDepartment of Pathology of the Federal University of Santa Catarina, Florianópolis, SC, Brazil.ORCID http://orcid.org/0000-0003-0188-6010

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe benefit of adding dual HER2 inhibition with Pertuzumab (P) and Trastuzumab (T) to chemotherapy (cT) in HER2-positive gastric or gastroesophageal junction (GEJ) cancer is not yet fully elucidated.

methodsA systematic search of PubMed, Cochrane Central, Embase, Web of Science, SciELO, and LILACS identified clinical trials investigating adjuvant or neoadjuvant regimens combining (P), (T) and (cT). Hazard ratios (HRs) and odds ratios (ORs) for binary endpoints were calculated, with 95% confidence intervals (CIs).

resultsFour clinical trials comprising a total of 1,225 patients were included. Dual HER2 blockade plus (cT) showed a significant benefit in survival analysis (HR 0.77, 95% CI 0.69-0.86), especially in terms of overall survival (HR 0.78, 95% CI 0.61-0.99) and progression-free survival (HR 0.73, 95% CI 0.62-0.85). Pathological response rates were higher compared with (cT) alone (OR 1.62, 95% CI 0.98-2.66). Treatment was associated with an increased overall adverse event rate (OR 1.48, 95% CI 1.32-1.66), particularly any-grade diarrhea, hypokalemia, fatigue, and pulmonary infection. Serious adverse events, including deaths and complications, were not significantly different (OR 0.87, 95% CI 0.51-1.49).

conclusionsThis systematic review and meta-analysis of clinical trials demonstrates that adding (P), (T) and (cT) improves survival and pathological response in HER2-positive gastric and GEJ tumors, with a manageable safety profile.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesEsophageal NeoplasmsStomach NeoplasmsTrastuzumabEsophagogastric JunctionHumansAntibodies, Monoclonal, HumanizedERBB2 protein, humanErb-b2 Receptor Tyrosine KinasespertuzumabTrastuzumabChemotherapyHER-2PertuzumabStomach neoplasmsTrastuzumab

Identifiers

PMID40982170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.